Evidence map›Paper›PMID 41258934›Full record

ArticleJournal of neurology2025

Assessment of IBM-FRS total score and specific functional domains in a large cohort of inclusion body myositis patients.

Alex Vicino, Antonio Lauletta, Silvia Bonanno, Adele Barbaccia, Maria Lucia Valentino, Barbara Risi, Eleonora Torchia, Marta Cheli, Paola Tonin, Guido Urbano and 28 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Alex VicinoNeuroimmunology and Neuromuscular Diseases Unit, Foundation IRCCS Carlo Besta Neurological Institute, Milan, Italy.
Antonio LaulettaNeuromuscular and Rare Disease Centre, Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), SAPIENZA University of Rome, Sant'Andrea Hospital, Rome, Italy.
Silvia BonannoNeuroimmunology and Neuromuscular Diseases Unit, Foundation IRCCS Carlo Besta Neurological Institute, Milan, Italy.
Adele BarbacciaDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Maria Lucia ValentinoIRCCS Istituto Delle Scienze Neurologiche Di Bologna, UOC Clinica Neurologica, Bologna, Italy.
Barbara RisiNeMO-Brescia Clinical Center for Neuromuscular Diseases, Brescia, Italy.
Eleonora TorchiaDepartment of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy.
Marta CheliNeuroimmunology and Neuromuscular Diseases Unit, Foundation IRCCS Carlo Besta Neurological Institute, Milan, Italy.
Paola ToninDepartment of Neurosciences, Biomedicine and Movement Sciences, Section of Clinical Neurology, University of Verona, Verona, Italy.
Guido UrbanoNeuromuscular Unit, Department of Neurosciences "Rita Levi Montalcini", Università Degli Studi Di Torino, Turin, Italy.
Elena SaccaniNeurology Unit, Department of Specialized Medicine, University Hospital of Parma, Parma, Italy.
Elena FaedoDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal Infantile Sciences, University of Genoa, Genoa, Italy.
Alessandra RuggieriNeuroimmunology and Neuromuscular Diseases Unit, Foundation IRCCS Carlo Besta Neurological Institute, Milan, Italy.
Eliana IannibelliNeuroimmunology and Neuromuscular Diseases Unit, Foundation IRCCS Carlo Besta Neurological Institute, Milan, Italy.
Michele Giovanni CroceDepartment of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy.
Dario ZoppiDepartment of Neurosciences, Reproductive Sciences and Odontostomatology, University Federico II of Naples, Naples, Italy.
Emanuele Maria CostantiniNeuroMuscular Omnicentre (NeMO), Ancona, Italy.
Andrea RigamontiDepartment of Neurosciences ASST Lecco, Neurology Unit, A. Manzoni Hospital, Lecco, Italy.
Giovanni ColaciccoThe NEMO Clinical Center Milan, Neurorehabilitation Unit, University of Milan, Milan, Italy.
Marina GrandisNeurology Unit, Department of Specialized Medicine, University Hospital of Parma, Parma, Italy.
Michela CocciaNeuroMuscular Omnicentre (NeMO) Ancona, AOU Delle Marche, Ancona, Italy.
Andrea BarpCentro NeMO Trento, Azienda Sanitaria Per I Servizi Sanitari (APSS), Pergine Valsugana, Trento, Italy.
Aurélie Marroun StephanNerve-Muscle Unit, Neurology Service, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Stefano CardaNeurorehabilitation Service, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Marie ThéaudinNerve-Muscle Unit, Neurology Service, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Sabrina RavagliaDepartment of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy.
Lucia RuggieroDepartment of Neurosciences, Reproductive Sciences and Odontostomatology, University Federico II of Naples, Naples, Italy.
Tiziana MonginiNeuromuscular Unit, Department of Neurosciences "Rita Levi Montalcini", Università Degli Studi Di Torino, Turin, Italy.
Lorenzo VerrielloHead-Neck and Neurosciences Department, Santa Maria della Misericordia University Hospital, Udine, Italy.
Gaetano VattemiDepartment of Neurosciences, Biomedicine and Movement Sciences, Section of Clinical Neurology, University of Verona, Verona, Italy.
Sara BortolaniDepartment of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy.
Valeria Ada SansoneThe NEMO Clinical Center Milan, Neurorehabilitation Unit, University of Milan, Milan, Italy.
Massimiliano FilostoNeMO-Brescia Clinical Center for Neuromuscular Diseases, Brescia, Italy.
Stefano Carlo PrevitaliNeuromuscular Repair Unit, Institute of Experimental Neurology (InSpe), Division of Neuroscience, IRCCS Ospedale San Raffaele, Milan, Italy.
Rocco LiguoriIRCCS Istituto Delle Scienze Neurologiche Di Bologna, UOC Clinica Neurologica, Bologna, Italy.
Carmelo RodolicoDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Matteo GaribaldiNeuromuscular and Rare Disease Centre, Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), SAPIENZA University of Rome, Sant'Andrea Hospital, Rome, Italy.
Lorenzo MaggiNeuroimmunology and Neuromuscular Diseases Unit, Foundation IRCCS Carlo Besta Neurological Institute, Milan, Italy. lorenzo.maggi@istituto-besta.it.ORCID http://orcid.org/0000-0002-0932-5173

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inclusion body myositis (IBM) is an acquired myopathy of older adults, associated with progressive weakness and functional limitations. The inclusion body myositis functional rating score (IBM-FRS) is a reliable tool for the assessment of disease severity, but poor data are available on its correlation with clinical features. In this cross-sectional, retrospective multicenter study, we analyzed IBM-FRS total score (TS) and its items in a cohort of 147 IBM patients, considering 4 functional domains (FD) (dysphagia, upper limb function, daily living and independence, lower limb function). We analyzed TS and FD values' correlations with demographic and clinical variables (onset, loss of walking ability, non-invasive ventilation, percutaneous gastrostomy-PEG) as well as between each FD and the remaining TS. Lower, hence worse, scores in the dysphagia domain (FD1) correlated with female gender (p < 0.01), dysphagia as presenting symptom (p < 0.01), and PEG use (p < 0.0001), but interestingly without correlation with time variables IBM-FRS total score or other domains. This may define a distinct phenotype with different onset and outcome. Worse scores in the upper and lower limb and daily living domains (FD2-FD4) were strongly associated with loss of ambulation, higher age at baseline, and longer disease duration (p < 0.001). We identified a cutoff value of 28/40, allowing to differentiate patients with less disease burden, potentially able to show better response in future clinical trials. Our study enriches the literature by correlating IBM-FRS total scores and its items with patient characteristics, offering important implications for clinical management, subgroup analysis, and future trials design.

Indexed as

Myositis, Inclusion BodySeverity of Illness IndexActivities of Daily LivingAgedAged, 80 and overCohort StudiesCross-Sectional StudiesDeglutition DisordersFemaleHumansMaleMiddle AgedRetrospective StudiesIBMIBM-FRSInclusion body myositisMyositis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.